CyBio Drop automated liquid handler
Freephone: 0800 257 428 Email: sales@alphatech.co.nz
Current methods used to measure ADCP rely on the isolation of primary human monocytes, ex vivo differentiation into macrophages and measurement of target cell engulfment. These assays are laborious and highly variable due to complex assay protocols and unqualified assay reagents. As a result, these current methods are difficult to establish in quality-controlled, drug development settings. The FcgammaRI ADCP Bioassay is a bioluminescent cell-based assay for measuring the potency and stability of antibodies and other biologics with Fc domains that bind and activate FcgammaRI. The assay consists of a genetically engineered Jurkat T cell line that expresses the high-affinity human FcgammaRI and a luciferase reporter. The bioassay workflow is simple, robust, consistent and overcomes many of the limitations of traditional methods.
